387 related articles for article (PubMed ID: 30526229)
1. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
[TBL] [Abstract][Full Text] [Related]
2. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
3. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
6. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
7. Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.
Manahan ER; Kuerer HM; Sebastian M; Hughes KS; Boughey JC; Euhus DM; Boolbol SK; Taylor WA
Ann Surg Oncol; 2019 Oct; 26(10):3025-3031. PubMed ID: 31342359
[TBL] [Abstract][Full Text] [Related]
8. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
9. Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.
Yang S; Axilbund JE; O'Leary E; Michalski ST; Evans R; Lincoln SE; Esplin ED; Nussbaum RL
Ann Surg Oncol; 2018 Oct; 25(10):2925-2931. PubMed ID: 29998407
[TBL] [Abstract][Full Text] [Related]
10. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
11. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
12. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
[TBL] [Abstract][Full Text] [Related]
14. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R
Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596
[TBL] [Abstract][Full Text] [Related]
15. Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
Neben CL; Zimmer AD; Stedden W; van den Akker J; O'Connor R; Chan RC; Chen E; Tan Z; Leon A; Ji J; Topper S; Zhou AY
J Mol Diagn; 2019 Jul; 21(4):646-657. PubMed ID: 31201024
[TBL] [Abstract][Full Text] [Related]
16. Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
Ademuyiwa FO; Salyer P; Ma Y; Fisher S; Colditz G; Weilbaecher K; Bierut LJ
Breast Cancer Res Treat; 2019 Nov; 178(1):151-159. PubMed ID: 31325073
[TBL] [Abstract][Full Text] [Related]
17. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
[TBL] [Abstract][Full Text] [Related]
18. Genetic Testing for Hereditary Breast Cancer: The Decision to Decline.
White VB; Walsh KK; Foss KS; Amacker-North L; Lenarcic S; McNeely L; White RL
Am Surg; 2018 Jan; 84(1):154-160. PubMed ID: 29428045
[TBL] [Abstract][Full Text] [Related]
19. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
[TBL] [Abstract][Full Text] [Related]
20. Expanded Gene Panel Use for Women With Breast Cancer: Identification and Intervention Beyond Breast Cancer Risk.
O'Leary E; Iacoboni D; Holle J; Michalski ST; Esplin ED; Yang S; Ouyang K
Ann Surg Oncol; 2017 Oct; 24(10):3060-3066. PubMed ID: 28766213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
